Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
FDA Resource: Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab
Crisis Management, Pharmacology,
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg): with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
The following link provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.